Nicola Maurea

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 129 publications

The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.

The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.

Journal: Journal of clinical medicine

Published: June 30, 2026

Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer.

Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer.

Journal: Cardio-oncology (London, England)

Published: June 03, 2026

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

Journal: International journal of molecular sciences

Published: May 04, 2026

Cholesterol metabolism in patients with cancer: pathophysiology, therapeutic options, and future perspectives

Cholesterol metabolism in patients with cancer: pathophysiology, therapeutic options, and future perspectives

Journal: Giornale italiano di cardiologia (2006)

Published: April 29, 2026

Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence.

Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: April 20, 2026

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

Journal: International journal of molecular sciences

Published: March 12, 2026

A Silent Saboteur of Immunotherapy: Antibiotic Use and Its Impact on Immune Checkpoint Inhibitors Efficacy, a Systematic Review and Meta-Analysis of Recent Studies.

A Silent Saboteur of Immunotherapy: Antibiotic Use and Its Impact on Immune Checkpoint Inhibitors Efficacy, a Systematic Review and Meta-Analysis of Recent Studies.

Journal: Cancers

Published: February 16, 2026

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.

Journal: Journal of translational medicine

Published: January 19, 2026

Hyaluronic acid and PEA-based Rutin-loaded nanoparticles as new cardioprotective tool against anthracycline-induced cardiotoxicity.

Hyaluronic acid and PEA-based Rutin-loaded nanoparticles as new cardioprotective tool against anthracycline-induced cardiotoxicity.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: December 22, 2025

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Journal: Journal of cardiovascular pharmacology

Published: October 06, 2025

Cardiovascular disease in adult cancer survivors: a new frontier for cardio-oncology

Cardiovascular disease in adult cancer survivors: a new frontier for cardio-oncology

Journal: Giornale italiano di cardiologia (2006)

Published: October 02, 2025

A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.

A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.

Journal: Cancers

Published: September 26, 2025

Showing 1-12 of 129

Last Updated: 09/26/2026